Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | ADRB3 | P13945 | 16/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.60 |
| ▸ | GABRP | O00591 | 1/20 | 0.48 |
| ▸ | GABRD | O14764 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.48 |
| ▸ | GABRE | P78334 | 1/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667471 | 1.00 | ALOX15 (0.69) | ALOX15ADRB3ADRB1GABRPGABRD | |
| SCHEMBL667469 | 1.00 | ALOX15 (0.69) | ALOX15ADRB3ADRB1GABRPGABRD | |
| Hydrochloric Acid SCHEMBL6136774 | 0.99 | ALOX15 (0.71) | ALOX15ADRB3ADRB1GABRPGABRD | |
| Hydrochloric Acid SCHEMBL6136778 | 0.99 | ALOX15 (0.71) | ALOX15ADRB3ADRB1GABRPGABRD | |
| Hydrochloric Acid SCHEMBL6136770 | 0.99 | ALOX15 (0.71) | ALOX15ADRB3ADRB1GABRPGABRD | |
| SCHEMBL8478597 | 0.91 | ADRB3 (0.58) | ALOX15ADRB3ADRB1ADRB2CYP1A2 | |
| SCHEMBL8478592 | 0.91 | ADRB3 (0.58) | ALOX15ADRB3ADRB1ADRB2CYP1A2 | |
| SCHEMBL8478595 | 0.91 | ADRB3 (0.58) | ALOX15ADRB3ADRB1ADRB2CYP1A2 | |
| SCHEMBL3511603 | 0.89 | ADRB3 (0.58) | ALOX15ADRB3ADRB1ADRB2 | |
| SCHEMBL3511600 | 0.89 | ADRB3 (0.58) | ALOX15ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1003744-B1 | 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2005-06-01 | — | — | EP | claimed |
| US-6657063-B1 | (4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino) ethoxy)phenyl)acetic acid derivatives; dietetics; hypotensive agents; non-insulin dependent diabetes treatment | PFIZER INC. | 2003-12-02 | — | — | US | claimed |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2003-01-02 | — | — | US | claimed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | claimed |
| EP-1099438-A2 | Use of APO B secretion/MTP inhibitors | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| EP-1099439-A2 | Use of apo B secretion/MTP inhibitors | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| EP-1099441-A2 | Compositions containing apo B secretion/MTP inhibitors and anti-obesity agents and use thereof | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| US-6124457-A | Process and intermediates for a β3 -adrenergic receptor agonist | PFIZER INC. (US) | 2000-09-26 | — | — | US | claimed |
| EP-1003744-A1 | 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2000-05-31 | — | — | EP | claimed |
| EP-0994105-A2 | 2-amino-pyridine intermediates for beta3-Adrenergic receptor agonists | Pfizer Products Inc. (US) | 2000-04-19 | — | — | EP | claimed |
| US-6001856-A | β-adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1999-12-14 | — | — | US | claimed |
| US-5977124-A | β-adrenergic agonists | PFIZER INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0920864-A1 | Combination therapy including a specific beta-3 agonist and an anorectic agent | Pfizer Products Inc. (US) | 1999-06-09 | — | — | EP | claimed |
| WO-1999007703-A1 | 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 1999-02-18 | — | — | WO | claimed |
| EP-0887079-A1 | Beta-Adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1998-12-30 | — | — | EP | claimed |
| EP-0828712-A1 | BETA-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1998-03-18 | — | — | EP | claimed |
| EP-0824519-A1 | BETA-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1998-02-25 | — | — | EP | claimed |
| WO-1996035671-A1 | β-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1996-11-14 | — | — | WO | claimed |
| WO-1996035670-A1 | β-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1996-11-14 | — | — | WO | claimed |
| JP-11092372-A | — | — | None | — | — | JP | disclosed |
| JP-11228447-A | — | — | None | — | — | JP | disclosed |
| US-20170319604-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS, INC. | 2017-11-09 | — | — | US | disclosed |
| WO-2017184811-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20150050371-A1 | Extract Formulations of Rhodamnia Cinerea And Uses Thereof | BIOTROPICS MALAYSIA BERHAD (MY) | 2015-02-19 | — | — | US | disclosed |
| WO-2013133685-A1 | EXTRACT FORMULATIONS OF RHODAMNIA CINEREA AND USES THEREOF | BIOTROPICS MALAYSIA BERHAD (MY) | 2013-09-12 | — | — | WO | disclosed |
| US-20120046364-A1 | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use | METABASIS THERAPEUTICS, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| EP-2247597-A1 | FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2010-11-10 | — | — | EP | disclosed |
| US-7829552-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100256061-A1 | GASTRIN COMPOUND FOR DIABETES TREATMENT | WARATAH PHARMACEUTICALS, INC. (CA) | 2010-10-07 | — | — | US | disclosed |
| EP-2209780-A2 | NONSTEROIDAL COMPOUNDS USEFUL AS MODULATORS OF GLUCOCORTICOID RECEPTOR AP-1 AND/OR NF- KAPPA B ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2010-07-28 | — | — | EP | disclosed |
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| WO-2009158380-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPA B ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20090232879-A1 | Thyromimetics for the Treatment of Fatty Liver Diseases | METABASIS THERAPEUTICS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| EP-2099767-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF- B ACTIVITY AND USE THEREOF | Brystol-Myers Squibb Company (US) | 2009-09-16 | — | — | EP | disclosed |
| EP-2094692-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF | Brystol-Myers Squibb Company (US) | 2009-09-02 | — | — | EP | disclosed |
| EP-2089389-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPA-B ACTIVITY | Bristol-Myers Squibb Company (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-2089355-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF- KAPPA B ACTIVITY AND USE THEREOF | Brystol-Myers Squibb Company (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009100171-A1 | FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009058944-A2 | NONSTEROIDAL COMPOUNDS USEFUL AS MODULATORS OF GLUCOCORTICOID RECEPTOR AP-1 AND /OR NF- KAPPA B ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20090118236-A1 | Novel Phosphorus-Containing Thyromimetics | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2009-05-07 | — | — | US | disclosed |
| EP-2049507-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | Brystol-Myers Squibb Company (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-7482368-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC (US) | 2009-01-27 | — | — | US | disclosed |
| US-20090012161-A9 | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012161-A9 | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-08 | — | — | US | disclosed |
| EP-1971363-A1 | COMBINATION TREATMENTS WITH GASTRIN AGONISTS FOR DIABETES AND RELATED DISEASES | Waratah Pharmaceuticals, Inc. (CA) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008106779-A1 | GASTRIN COMPOUND FOR DIABETES TREATMENT | WARATAH PHARMACEUTICALS INC. (CA) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008106775-A1 | COMBINATION TREATMENT FOR DIABETES USING AN EGF RECEPTOR LIGAND AND A GASTRIN COMPOUND | WARATAH PHARMACEUTICALS INC. (CA) | 2008-09-12 | — | — | WO | disclosed |
| EP-1404653-B1 | TRIAMIDE-SUBSTITUTED INDOLES, BENZOFURANES AND BENZOTHIOPHENES AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) AND/OR APOLIPOPROTEIN B (APO B) SECRETION | PFIZER PROD INC (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008057856-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057855-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-I, AND/OR NP-KAPPA-B ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057862-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057857-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| US-7348355-B2 | Treating obesity with the Microsomal triglyceride transfer protein inhibitor (S) N-{2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl}-1-methyl-5-[4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamido]-1H-indole-2-carboxamide and another lipid lowering agent such as a statin or fibrate | PFIZER INC. (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2008021926-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1268404-B1 | MALONAMIC ACIDS AND DERIVATIVES THEREOF AS THYROID RECEPTOR LIGANDS | PFIZER PROD INC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070173548-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | CHIANG YUAN-CHING P | 2007-07-26 | — | — | US | disclosed |
| US-20070149451-A1 | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent | HOLMES DAVID G | 2007-06-28 | — | — | US | disclosed |
| WO-2007062531-A1 | COMBINATION TREATMENTS WITH GASTRIN AGONISTS FOR DIABETES AND RELATED DISEASES | WARATAH PHARMACEUTICALS, INC. (CA) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129435-A1 | Pharmaceutical Composition For Treating Stress Incontinence And/Or Mixed Incontinence | MICHEL MARTIN | 2007-06-07 | — | — | US | disclosed |
| US-20070129435-A1 | Pharmaceutical Composition For Treating Stress Incontinence And/Or Mixed Incontinence | MICHEL MARTIN | 2007-06-07 | — | — | US | disclosed |
| US-7202275-B2 | Malonamic acids and derivatives thereof as thyroid receptor ligands | WARNER LAMBERT COMPANY LLC (US) | 2007-04-10 | — | — | US | disclosed |
| WO-2007036543-A1 | BETA-3-AGONIST USE FOR TREATING KIDNEY AND BLADDER TROUBLES OF A PATIENT WITH SPINAL CORD DAMAGES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-05 | — | — | WO | disclosed |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | MICHEL MARTIN C | 2007-04-05 | — | — | US | disclosed |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | MICHEL MARTIN C | 2007-04-05 | — | — | US | disclosed |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | MICHEL MARTIN C | 2007-04-05 | — | — | US | disclosed |
| EP-1769792-A1 | Use of a beta-3 adrenoceptor agonist for the treatment of renal and bladder problems | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2007-04-04 | — | — | EP | disclosed |
| US-20060194772-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2006-08-31 | — | — | US | disclosed |
| EP-1687030-A2 | COMBINATION OF A DPP IV INHIBITOR AND AN ANTI-OBESITY OR APPETITE REGULATING AGENT | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| EP-1157695-B1 | Method of treating obesity using a neurotensin receptor ligand | PFIZER PROD INC (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060084700-A1 | Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-20 | — | — | US | disclosed |
| US-20050288335-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| US-6979692-B2 | such as (S)-1-ethyl-5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid-[2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl]amide; for treatment of obesity and lipid disorders; diabetes | PFIZER INC. (US) | 2005-12-27 | — | — | US | disclosed |
| EP-1297833-B1 | Indole carboxylic acids as thyroid receptor ligands | PFIZER PROD INC (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-0994105-B1 | 2-amino-pyridine intermediates for beta3-Adrenergic receptor agonists | PFIZER PROD INC (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1148054-B1 | Thyroid receptor ligands | PFIZER PROD INC (US) | 2005-11-23 | — | — | EP | disclosed |
| US-6960604-B2 | Thyroid receptor ligands | PFIZER INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050222040-A1 | Vertebrate peptide modulators of lipid metabolism | BLM GROUP, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| US-6949572-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050209333-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | CHIANG YUAN-CHING P | 2005-09-22 | — | — | US | disclosed |
| US-6930107-B2 | 6-azauracil derivatives as thyroid receptor ligands | PFIZER INC. (US) | 2005-08-16 | — | — | US | disclosed |
| US-6924310-B2 | Malonamic acids and derivatives thereof as thyroid receptor ligands | PFIZER INC. (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1088819-B1 | 6-azauracil derivatives as thyroid receptor ligands | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005049088-A2 | COMBINATION OF A DPP IV INHIBITOR AND AN ANTIOBESITY OR APPETITE REGULATING AGENT | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| EP-1003744-B1 | 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050080108-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2005-04-14 | — | — | US | disclosed |
| EP-1499317-A1 | TREATMENT OF DIABETES AND DIABETIC COMPLICATIONS WITH NHE-1 INHIBITORS | Pfizer Products Inc. (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1078924-B1 | Intermediates and a process for producing beta-adrenergic receptor agonists | PFIZER PROD INC (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6787652-B1 | LOWERING LIPIDS AND SERUM CHOLESTEROL WITHOUT GENERATING ADVERSE CARDIAC EFFECTS; 4,5-DIHYDRO-3,5-DIOXO-1,2,4-TRIAZINE DERIVATIVES | PFIZER, INC. | 2004-09-07 | — | — | US | disclosed |
| US-20040157844-A1 | 6-azauracil derivatives as thyroid receptor ligands | DOW ROBERT L (US) | 2004-08-12 | — | — | US | disclosed |
| US-20040110951-A1 | Thyroid receptor ligands | CHIANG YUAN-CHING P (US) | 2004-06-10 | — | — | US | disclosed |
| US-6734175-B2 | ADMINISTERING TO AN OBESE PATIENT OR ONE AT RISK OF BECOMING OBESE A THERAPEUTIC COMPOUND THAT ATTENUATES THE BINDING OF AGOUTI-RELATED PROTEIN TO MELANOCORTIN RECEPTORS, FREE OF BINDING OF ALPHA-MELANOCYTE STIMULATING HORMONE TO RECEPTOR | PFIZER INC. | 2004-05-11 | — | — | US | disclosed |
| US-20040087625-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2004-05-06 | — | — | US | disclosed |
| US-20040077694-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | CHIANG YUAN-CHING P (US) | 2004-04-22 | — | — | US | disclosed |
| US-6723744-B2 | FOR THERAPY OF OBESITY, OVERWEIGHT CONDITION, HYPERLIPIDEMIA, GLAUCOMA, CARDIAC ARRHYTHMIAS, SKIN DISORDER, THYROID DISEASE, HYPOTHYROIDISM, THYROID CANCER, DIABETES, ATHEROSCLEROSIS, HYPERTENSION, CORONARY HEART DISEASE, HYPERCHOLESTEREMIA | PFIZER, INC. | 2004-04-20 | — | — | US | disclosed |
| US-6720351-B2 | 1H-INDOLE-2-CARBOXYLIC ACID (2-(BENZYL(METHYL)AMINO) -2-OXO-1-PHENYLETHYL)AMIDES; TRIAMIDE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) AND APOLIPOPROTEIN B (APO B) INHIBITORS; OBESITY; ANTILIPEMIC AGENTS | PFIZER INC. | 2004-04-13 | — | — | US | disclosed |
| EP-1404653-A1 | TRIAMIDE-SUBSTITUTED INDOLES, BENZOFURANES AND BENZOTHIOPHENES AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) AND/OR APOLIPOPROTEIN B (APO B) SECRETION | Pfizer Products Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-0995748-B1 | Growth hormone secretagogues | PFIZER PROD INC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6713489-B2 | TREATMENT OF ATHEROSCLEROSIS, OBESITY, DIABETES, HYPERLIPIDEMIA, HYPERLIPOPROTEINEMIA, HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDEMIA, HYPOALPHALIPOPROTEINEMIA, PANCREATITIS, MYOCARDIAL INFARCTION, STROKE, RESTENOSIS, OR SYNDROME X | PFIZER INC | 2004-03-30 | — | — | US | disclosed |
| US-6699832-B2 | MAY CONTAIN ANOTHER COMPOUND TO TREAT DIABETES, SEXUAL DYSFUNCTION, ATHEROSCLEROSIS, INSULIN RESISTANCE, IMPAIRED GLUCOSE TOLERANCE, HYPERCHOLESTEROLEMIA OR HYPERTRIGLYCERIDEMIA | PFIZER INC. | 2004-03-02 | — | — | US | disclosed |
| US-6686359-B2 | ANIMAL GROWTH REGULATORS; OSTEOPOROSIS; CONGESTIVE HEART FAILURE; MUSCULAR DISORDERS | PFIZER INC. | 2004-02-03 | — | — | US | disclosed |
| US-6664291-B2 | Aromatic amidealkyl acid or ester or amide or hydroxy derivatives are useful in the treatment of obesity, overweight condition, hyperlipidemia, glucoma, cardiac arrhythmias, thyroid disease, skin disoders and diabetes | PFIZER, INC. | 2003-12-16 | — | — | US | disclosed |
| US-6657063-B1 | (4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino) ethoxy)phenyl)acetic acid derivatives; dietetics; hypotensive agents; non-insulin dependent diabetes treatment | PFIZER INC. | 2003-12-02 | — | — | US | disclosed |
| US-6657063-B1 | (4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino) ethoxy)phenyl)acetic acid derivatives; dietetics; hypotensive agents; non-insulin dependent diabetes treatment | PFIZER INC. | 2003-12-02 | — | — | US | disclosed |
| WO-2003092694-A1 | TREATMENT OF DIABETES AND DIABETIC COMPLICATIONS WITH NHE-1 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| US-20030212104-A1 | Treatment of diabetes and diabetic complications with NHE-1 inhibitors | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-20030187053-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| US-6620830-B2 | Certain thiazolidinedione, oxadiazolidinedione, and triazolone compounds which are thyroid receptor ligands | PFIZER, INC. | 2003-09-16 | — | — | US | disclosed |
| US-20030130284-A1 | Growth hormone secretagogues | CARPINO PHILIP A (US) | 2003-07-10 | — | — | US | disclosed |
| US-6559150-B2 | Neurotransmitter stimulants; antidiabetic agents; congestive heart failure; obesity; frailty; maintaining renal and catabolic homeostasis; bone fracture repair; reducing cachexia and protein loss; muscle strength and burns. | PFIZER INC. | 2003-05-06 | — | — | US | disclosed |
| US-20030078289-A1 | Indole carboxylic acids as thyroid receptor ligands | ASPNES GARY E (US) | 2003-04-24 | — | — | US | disclosed |
| EP-1297833-A1 | Indole carboxylic acids as thyroid receptor ligands | Pfizer Products Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20030040535-A1 | Tetrazole compounds as thyroid receptor ligands | ASPNES GARY E (US) | 2003-02-27 | — | — | US | disclosed |
| US-6514966-B2 | Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine | PFIZER INC. | 2003-02-04 | — | — | US | disclosed |
| WO-2003002533-A1 | TRIAMIDE-SUBSTITUTED INDOLES, BENZOFURANES AND BENZOTHIOPHENES AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) AND/OR APOLIPOPROTEIN B (APO B) SECRETION | PFIZER PRODUCTS INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| EP-1268404-A1 | MALONAMIC ACIDS AND DERIVATIVES THEREOF AS THYROID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2003-01-02 | — | — | US | disclosed |
| US-20020198152-A1 | Treatments for obesity and methods for identifiying compounds useful for treating obesity | HADCOCK JOHN R (US) | 2002-12-26 | — | — | US | disclosed |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | RUGGERI ROGER (US) | 2002-09-19 | — | — | US | disclosed |
| US-6451783-B1 | Treatments for obesity and methods for identifying compounds useful for treating obesity | PFIZER INC. | 2002-09-17 | — | — | US | disclosed |
| US-6451587-B1 | ASYMMETRIC REDUCTION OF A KETONE TO AN ALCOHOL, WHICH COMPRISES: CONTACTING THE KETONE WITH A MICROORGANISM, OR AN ENZYME REDUCTION SYSTEM CAPABLE OF ACCOMPLISHING THE SUBJECT REDUCTION COMPRISING AN ENZYME DERIVED FROM SAID MICROORGANISM | PFIZER INC. | 2002-09-17 | — | — | US | disclosed |
| US-6441181-B1 | MAKING (4-(2-(2-(6-AMINOPYRIDIN-3-YL)-2(R)-HYDROXYETHYLAMINO)ETHOXY) PHENYLACETIC ACID; DEPROTECTION OF PYRROLE DERIVATIVE; INTERMEDIATES | PFIZER INC. | 2002-08-27 | — | — | US | disclosed |
| US-6441015-B2 | OBESITY, ANTIDIABETIC AGENTS, CARDIOVASCULAR DISORDERS | PFIZER INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020094992-A1 | Intermittent administration of a growth hormone secretagogue | MACLEAN DAVID B (US) | 2002-07-18 | — | — | US | disclosed |
| US-20020065277-A1 | Treatments for obesity and methods for identifiying compounds useful for treating obesity | HADCOCK JOHN R (US) | 2002-05-30 | — | — | US | disclosed |
| US-20020045757-A1 | Compound and process for producing beta-adrenergic receptor agonist | SCOTT ROBERT W (US) | 2002-04-18 | — | — | US | disclosed |
| US-20020045622-A1 | Growth hormone secretagogues | CARPINO PHILIP A (US) | 2002-04-18 | — | — | US | disclosed |
| US-6369075-B1 | 7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B | PFIZER, INC. | 2002-04-09 | — | — | US | disclosed |
| US-6358951-B1 | ADMINISTERING PYRAZOLO(4,3-C)PYRIDINE DERIVATIVE TO TREAT OBESITY, CONGESTIVE HEART FAILURE, OSTEOPOROSIS, AGING, BONE AND MUSCULAR DISORDERS | PFIZER INC. | 2002-03-19 | — | — | US | disclosed |
| EP-1186293-A2 | Intermittent administration of a growth hormone secretagogue | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| US-20020006946-A1 | Tetrazole compounds as thyroid receptor ligands | PFIZER INC. | 2002-01-17 | — | — | US | disclosed |
| US-20010051657-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | PFIZER INC. | 2001-12-13 | — | — | US | disclosed |
| US-20010051645-A1 | Thyroid receptor ligands | CHIANG YUAN-CHING P (US) | 2001-12-13 | — | — | US | disclosed |
| US-20010046956-A1 | Methods of treating obesity using a neurotensin receptor ligand | HADCOCK JOHN R (US) | 2001-11-29 | — | — | US | disclosed |
| EP-1157695-A1 | Method of treating obesity using a neurotensin receptor ligand | Pfizer Products Inc. (US) | 2001-11-28 | — | — | EP | disclosed |
| US-20010039277-A1 | Compounds for the treatment of obesity | ELLIOTT RICHARD L (US) | 2001-11-08 | — | — | US | disclosed |
| EP-1148054-A1 | Thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2001072692-A1 | MALONAMIC ACIDS AND DERIVATIVES THEREOF AS THYROID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2001-10-04 | — | — | WO | disclosed |
| US-6297382-B1 | (4-(2-(2-(6-AMINOPYRIDIN-3-YL)-2(R)-HYDROXYETHYLAMINO)ETHOXY) PHENYLACETIC ACID, | PFIZER, INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-1127882-A1 | Tetrazole compounds as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1125579-A2 | Uses of agrp-melanocortin receptor binding modulating compounds | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1099438-A2 | Use of APO B secretion/MTP inhibitors | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1099439-A2 | Use of apo B secretion/MTP inhibitors | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1099441-A2 | Compositions containing apo B secretion/MTP inhibitors and anti-obesity agents and use thereof | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1088819-A2 | 6-azauracil derivatives as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-1078924-A1 | Intermediates and a process for producing beta-adrenergic receptor agonists | Pfizer Products Inc. (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6187778-B1 | EATING AND CARDIOVASCULAR DISORDERS | PFIZER INC. | 2001-02-13 | — | — | US | disclosed |
| WO-2000066578-A1 | COMPOUNDS FOR THE TREATMENT OF OBESITY | PFIZER PRODUCTS INC. (US) | 2000-11-09 | — | — | WO | disclosed |
| US-6124457-A | Process and intermediates for a β3 -adrenergic receptor agonist | PFIZER INC. (US) | 2000-09-26 | — | — | US | disclosed |
| US-6090942-A | Process and intermediates for a β3 -adrenergic receptor agonist | PFIZER INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-1003744-A1 | 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-0995748-A1 | Growth hormone secretagogues | Pfizer Products Inc. (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0994105-A2 | 2-amino-pyridine intermediates for beta3-Adrenergic receptor agonists | Pfizer Products Inc. (US) | 2000-04-19 | — | — | EP | disclosed |
| US-6001856-A | β-adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1999-12-14 | — | — | US | disclosed |
| US-5998463-A | Glycogen phosphorylase inhibitors | PFIZER INC (US) | 1999-12-07 | — | — | US | disclosed |
| US-5977124-A | β-adrenergic agonists | PFIZER INC. (US) | 1999-11-02 | — | — | US | disclosed |
| JP-H11228447-A | COMBINATION THERAPY | PFIZER PROD INC | 1999-08-24 | — | — | JP | disclosed |
| EP-0920864-A1 | Combination therapy including a specific beta-3 agonist and an anorectic agent | Pfizer Products Inc. (US) | 1999-06-09 | — | — | EP | disclosed |
| EP-0920864-A1 | Combination therapy including a specific beta-3 agonist and an anorectic agent | Pfizer Products Inc. (US) | 1999-06-09 | — | — | EP | disclosed |
| JP-H1192372-A | BETA-ADRENERGIC AGONIST FOR REDUCING EMACIATION CONDITION | PFIZER INC | 1999-04-06 | — | — | JP | disclosed |
| WO-1999007703-A1 | 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 1999-02-18 | — | — | WO | disclosed |
| EP-0887079-A1 | Beta-Adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1998-12-30 | — | — | EP | disclosed |
| EP-0828712-A1 | BETA-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1998-03-18 | — | — | EP | disclosed |
| EP-0824519-A1 | BETA-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996035671-A1 | β-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1996-11-14 | — | — | WO | disclosed |
| WO-1996035671-A1 | β-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1996-11-14 | — | — | WO | disclosed |
| WO-1996035670-A1 | β-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (33 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194772-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | ALOX15 2168/4885ADRB3 1788/4885ADRB1 1344/4885 |
| US-20040087625-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | ALOX15 2597/4885ADRB3 1609/4885ADRB1 750/4885 |
| US-20070149451-A1 | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent | GIPR, DPP4, MC4R | ALOX15 4771/4885ADRB3 699/4885ADRB1 940/4885 |
| US-20030212104-A1 | Treatment of diabetes and diabetic complications with NHE-1 inhibitors | NHERF1, SLC5A1, SLC5A2 | ALOX15 3327/4885ADRB3 2267/4885ADRB1 1536/4885 |
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | PYGL, THRA, THOP1 | ALOX15 1968/4885ADRB3 1247/4885ADRB1 2591/4885 |
| US-20120046364-A1 | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use | THRB, TSHR, THRA | ALOX15 1755/4885ADRB3 801/4885ADRB1 865/4885 |
| US-20060084700-A1 | Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract | ADRB3, ADRB2, ADRB1 | ALOX15 1487/4885ADRB3 1/4885ADRB1 3/4885 |
| US-20050288335-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | ALOX15 2168/4885ADRB3 1788/4885ADRB1 1344/4885 |
| US-20020045757-A1 | Compound and process for producing beta-adrenergic receptor agonist | ADRB1, ADRB2, ADRA2B | ALOX15 1182/4885ADRB3 8/4885ADRB1 1/4885 |
| US-20090118236-A1 | Novel Phosphorus-Containing Thyromimetics | THRA, PYGL, THRB | ALOX15 1467/4885ADRB3 1276/4885ADRB1 2349/4885 |
| US-20030187053-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | ALOX15 2597/4885ADRB3 1609/4885ADRB1 750/4885 |
| US-20040157844-A1 | 6-azauracil derivatives as thyroid receptor ligands | TSHR, THRA, THRB | ALOX15 2109/4885ADRB3 306/4885ADRB1 84/4885 |
| US-20030040535-A1 | Tetrazole compounds as thyroid receptor ligands | THRA, TSHR, THRB | ALOX15 632/4885ADRB3 219/4885ADRB1 172/4885 |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | ADRB3, ADRB2, ADRB1 | ALOX15 1537/4885ADRB3 1/4885ADRB1 3/4885 |
| US-20070173548-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | THRA, MC1R, TSHR | ALOX15 631/4885ADRB3 608/4885ADRB1 408/4885 |
| US-20050209333-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | THRA, MC1R, TSHR | ALOX15 631/4885ADRB3 608/4885ADRB1 408/4885 |
| US-20170319604-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | THRB, THRA, TSHR | ALOX15 2864/4885ADRB3 59/4885ADRB1 49/4885 |
| US-20010039277-A1 | Compounds for the treatment of obesity | NPY1R, NPY4R, NPY2R | ALOX15 338/4885ADRB3 110/4885ADRB1 163/4885 |
| US-20010051645-A1 | Thyroid receptor ligands | TSHR, THRB, THRA | ALOX15 774/4885ADRB3 37/4885ADRB1 33/4885 |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | APOB, CETP, PNLIP | ALOX15 1151/4885ADRB3 298/4885ADRB1 261/4885 |
| US-20020006946-A1 | Tetrazole compounds as thyroid receptor ligands | TSHR, THRA, THRB | ALOX15 734/4885ADRB3 187/4885ADRB1 202/4885 |
| US-20020045622-A1 | Growth hormone secretagogues | GHSR, GHRHR, GIPR | ALOX15 1088/4885ADRB3 140/4885ADRB1 154/4885 |
| US-20090012161-A9 | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | ADRB3, ADRB2, ADRB1 | ALOX15 1609/4885ADRB3 1/4885ADRB1 3/4885 |
| US-20070129435-A1 | Pharmaceutical Composition For Treating Stress Incontinence And/Or Mixed Incontinence | ADRB3, ADRB2, ADRB1 | ALOX15 628/4885ADRB3 1/4885ADRB1 3/4885 |
| US-20090232879-A1 | Thyromimetics for the Treatment of Fatty Liver Diseases | TSHR, THRA, FABP1 | ALOX15 314/4885ADRB3 148/4885ADRB1 261/4885 |
| US-20030130284-A1 | Growth hormone secretagogues | GHSR, GHRHR, GIPR | ALOX15 1088/4885ADRB3 140/4885ADRB1 154/4885 |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | ALOX15 1638/4885ADRB3 2257/4885ADRB1 3245/4885 |
| US-20040077694-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | THRA, MC1R, TSHR | ALOX15 612/4885ADRB3 583/4885ADRB1 357/4885 |
| US-20010051657-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | THRA, MC1R, THRB | ALOX15 529/4885ADRB3 621/4885ADRB1 309/4885 |
| US-20030078289-A1 | Indole carboxylic acids as thyroid receptor ligands | THRA, MC1R, THRB | ALOX15 1206/4885ADRB3 90/4885ADRB1 72/4885 |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | PYGL, PHOSPHO1, LIPE | ALOX15 1277/4885ADRB3 1960/4885ADRB1 3052/4885 |
| US-20050080108-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | ALOX15 2039/4885ADRB3 1767/4885ADRB1 1201/4885 |
| US-20040110951-A1 | Thyroid receptor ligands | TSHR, THRB, THRA | ALOX15 774/4885ADRB3 37/4885ADRB1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.